Biomarker-Based Infectious Disease Testing Market To Reach $ 15 Billion
Bruce Carlson of Kalorama Information.
Biomarkers include over 1000 substances that serve as reagents, consumables and / or test components for a number of diagnostic and research applications related to medicine. Substances that detect and measure genetic changes in patient samples are also included in sales statistics.
Biomarkers of infectious agents include proteins (antigens), antibodies produced in response to the presence of infectious agents, and genomic markers. More recently, technologies such as mass spectrometry are applied to the identification of pathogens.
Global Diagnostic Biomarker Market Report Says Infectious Disease-Based Testing Using Biomarkers Will Grow From $ 14.8 Billion In Sales To $ 20.7 Billion In Sales. From 2021 to 2027, the compound annual revenue growth will be 5.8% per annum. This does not include COVID-19 testing, which has generated revenue lately.
The characteristic results of a mass spectrometric analysis of a specific pathogen could be considered as a biomarker for that pathogen. However, for the purposes of this study, biomarkers of infectious diseases rely on three major technologies: laboratory immunoassays, molecular tests and rapid immunoassays.
Laboratory immunoassays will account for over 60% of global sales of long-term infectious disease biomarkers. This trend will reflect the well-established position of technology in the detection of a wide range of common pathogens, including antigens or antibodies associated with pneumonia, influenza, Clostridium difficile (C. diff), hepatitis C, HIV, herpes simplex virus (HSV) and Lyme disease. Enzyme-related immunoassays are particularly well suited for diagnosing these conditions.
For more complex infectious disease testing applications, polymerase chain reaction (PCR), microarrays and other molecular technologies will capture an increasing share of global value and volume. These technologies identify DNA, RNA and genes associated with pathogens, allowing a more definitive diagnosis.
Among the infectious agents identified by molecular tests are HPV, Chlamydia trachomatis/Neisseria gonorrhea (CT / NG) and tuberculosis. In addition, these tests are increasingly used to detect resistance genes linked to nosocomial infections and disease-resistant pathogens.
Rapid immunoassays based on lateral flow immunochromatography techniques are being developed to enable an increasing number of infectious diseases to be detected in clinics, doctor’s offices, hospital emergency rooms, homes patients and other points of care.
Specific tests now available in this area include those for bacterial vaginosis (BV), chlamydia, dengue, Ebola, HIV, influenza, legionellosis, malaria, rotavirus, respiratory syncytial virus (RSV), group AT Streptococcus, Treponema pallidum, and Trichomonas vaginalis. Sample sources for rapid immunoassays extend to a full range of substances, including whole blood, serum, urine, nasal and throat swabs, stool specimens and vaginal swabs.
Companies such as Roche, Abbott, BioMerieux, Bio-Rad and Cepheid participate, among others, in this market. Kalorama’s estimates are the total revenues made by companies like these from the sale of diagnostic products. The Kalorama report states that growth will be fastest in molecular assays, moderate in rapid tests, and slowest in laboratory immunoassays.
Bruce Carlson is the editor of Kalorama Information, which is part of the Science and Medicine Group. Kalorama’s market report on Diagnostic Biomarkers can be found on the Kalorama website.
Disclosure: LabPulse.com is a sister company of Kalorama Information.
Copyright © 2021 LabPulse.com